Candel Therapeutics, Inc. (CADL)

Current Report Filed: 2026-05-15

Candel presented extended follow-up data from a Phase 3 clinical trial of aglatimagene besadenovec for localized prostate cancer at the American Urological Association 2026 Annual Meeting, suggesting progression toward potential regulatory approval.
The company held a simultaneous investor webcast on the same day as the medical conference presentation, indicating efforts to manage investor communications and market perception around clinical trial results.
This is a Regulation FD disclosure filing with furnished exhibits that are explicitly not incorporated by reference, limiting the legal liability and forward-looking statement implications typically associated with filed documents.

Current Report Filed: 2026-05-14

Candel Therapeutics announced Q1 2026 financial results on May 14, 2026, with the full details provided in a press release attached as Exhibit 99.1, though the specific financial metrics are not disclosed in this 8-K cover document.
The filing is designated as furnished rather than filed under Section 18 of the Exchange Act, meaning it carries reduced liability exposure and is not automatically incorporated into other SEC filings unless expressly referenced.
Paul Peter Tak, M.D., Ph.D., FMedSci is identified as President and CEO, indicating stable leadership at the biotech company as of the filing date.

Quarterly Report Filed: 2026-05-14

The filing shows significant debt financing activity through Trinity Capital Inc. with multiple tranches of term loans dated October 2025, indicating the company is relying on external financing to fund operations, which may dilute existing shareholders and increase financial obligations.
Multiple warrant issuances (Series B, NC Ohio Trust, Lender Warrants, and Conditional Warrants) suggest substantial equity dilution and indicate the company is using warrants as financing instruments, which could pressure share price upon exercise.
The company conducted public offerings and at-the-market (ATM) offering activities in late 2024 and early 2025, demonstrating capital raising efforts but also signaling potential cash burn concerns requiring continuous market access.
Presence of a Brigham and Women's Hospital license agreement (dated 2018-2020) indicates clinical partnerships and intellectual property partnerships that may provide validation and commercialization pathways for therapeutic programs.

Insider Trading Filed: 2026-04-02

Nicoletta Loggia, a director of Candel Therapeutics, Inc. (CADL), acquired 779 stock options on March 31, 2026 with an exercise price of $4.9 per share. This indicates potential confidence in the company's future performance.
The stock options granted to Loggia are fully vested at the time of grant, suggesting the company may be compensating directors in equity to preserve cash.
The transaction represents a direct ownership stake for Loggia, which could align her interests with those of other shareholders.

Insider Trading Filed: 2026-04-02

Insider Joseph C. Papa acquired 2,795 stock options of Candel Therapeutics, Inc. (CADL) on March 31, 2026, exercisable at $4.114 per share until March 31, 2036.
The stock option grant was made in lieu of normal quarterly cash payments, indicating the insider's confidence in the company's future prospects.
The substantial option grant and the fact that it was fully vested at the time of issuance suggest that the insider believes the stock is undervalued and expects it to appreciate significantly in the coming years.

Insider Trading Filed: 2026-04-02

The reporting person, Paul B. Manning, was granted a stock option to purchase 4,618 shares of the company's common stock at an exercise price of $4.114 per share.
The option was granted on 03/31/2026 and will expire on 03/31/2036, with the underlying shares fully vested at the time of grant.
This stock option grant appears to be in lieu of normal quarterly cash payments, indicating the company may be compensating directors through equity awards.

Current Report Filed: 2026-03-12

Candel Therapeutics announced its Q4 2025 and full-year 2025 financial results, highlighting the company's progress and performance.
The company did not provide any forward-looking guidance or commentary on its pipeline or upcoming milestones in the 8-K filing.
No material changes to Candel's leadership, agreements, or other significant corporate events were reported in this 8-K filing.

Annual Report Filed: 2026-03-12

Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company has licensed technology from Brigham and Women's Hospital and acquired assets from Peripagen Inc.
Candel has secured financing through a loan agreement with Trinity Capital Inc. and an at-the-market (ATM) offering. The company also has outstanding warrants that could provide additional funding if exercised.
Candel reported no revenue in 2024 and 2025, as it remains in the clinical development stage. The company's expenses are primarily related to R&D and general & administrative costs.

Current Report Filed: 2026-02-23

Candel Therapeutics, Inc. has launched a public offering of 18.3 million shares of its common stock, with an additional 2.8 million shares available through an overallotment option.
The company plans to use the estimated $93.5 million in net proceeds to support critical launch readiness, medical affairs, pre-commercialization, and ongoing development of its lead candidate CAN-2409 for prostate and lung cancer.
Assuming the base offering amount, the company expects its cash and cash equivalents to fund operations and capital expenditures into the first quarter of 2028.

Current Report Filed: 2026-02-19